[go: up one dir, main page]

DE69535221D1 - Cardiotrophin und verwendung davon - Google Patents

Cardiotrophin und verwendung davon

Info

Publication number
DE69535221D1
DE69535221D1 DE69535221T DE69535221T DE69535221D1 DE 69535221 D1 DE69535221 D1 DE 69535221D1 DE 69535221 T DE69535221 T DE 69535221T DE 69535221 T DE69535221 T DE 69535221T DE 69535221 D1 DE69535221 D1 DE 69535221D1
Authority
DE
Germany
Prior art keywords
chf
disorders
neurological
activity
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535221T
Other languages
English (en)
Other versions
DE69535221T2 (de
Inventor
Joffre Baker
Kenneth Chien
Kathleen King
Diane Pennica
William Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Genentech Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/233,609 external-priority patent/US5534615A/en
Application filed by Genentech Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69535221D1 publication Critical patent/DE69535221D1/de
Publication of DE69535221T2 publication Critical patent/DE69535221T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69535221T 1994-04-25 1995-04-06 Cardiotrophin und verwendung davon Expired - Lifetime DE69535221T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US233609 1994-04-25
US08/233,609 US5534615A (en) 1994-04-25 1994-04-25 Cardiac hypertrophy factor and uses therefor
US08/286,304 US5571893A (en) 1994-04-25 1994-08-05 Cardiac hypertrophy factor
US286304 1994-08-05
PCT/US1995/004467 WO1995029237A1 (en) 1994-04-25 1995-04-06 Cardiotrophin and uses therefor

Publications (2)

Publication Number Publication Date
DE69535221D1 true DE69535221D1 (de) 2006-10-26
DE69535221T2 DE69535221T2 (de) 2007-09-13

Family

ID=26927082

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535221T Expired - Lifetime DE69535221T2 (de) 1994-04-25 1995-04-06 Cardiotrophin und verwendung davon

Country Status (10)

Country Link
US (5) US5624806A (de)
EP (1) EP0755446B1 (de)
JP (1) JP3906314B2 (de)
AT (1) ATE339503T1 (de)
CA (1) CA2188017C (de)
DE (1) DE69535221T2 (de)
DK (1) DK0755446T3 (de)
ES (1) ES2276393T3 (de)
MX (1) MX9604985A (de)
WO (1) WO1995029237A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) * 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
US7258983B2 (en) * 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US5869274A (en) * 1995-08-09 1999-02-09 Zymed Laboratories, Inc. Immuno-histochemical method that reduces background staining
AU768995B2 (en) * 1996-02-14 2004-01-15 Genentech Inc. Cardiotrophin and uses therefor
EP0885294A2 (de) * 1996-02-14 1998-12-23 Genentech, Inc. Cardiotrophin und verwendung davon
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
PT1012280E (pt) * 1997-06-11 2005-02-28 Borean Pharma As Modulo de trimerizacao
US6875567B1 (en) * 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
US6610480B1 (en) * 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
EP2016951B1 (de) 1998-03-17 2012-06-27 Genentech, Inc. VEGF- und BMP1-homologe Peptide
GB9808796D0 (en) * 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
US7208576B2 (en) * 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
DE60020213T2 (de) * 1999-01-21 2006-02-02 Genentech Inc., San Francisco Zusammensetzungen sowie verfahren zur diagnose und behandlung von tumorerkrankungen
EP1161533A1 (de) * 1999-03-09 2001-12-12 Atlantic Biopharmaceuticals, Inc. EXPRESSION VON HUMANEM ALPHA-FETOPROTEIN IN SäUGETIERZELLEN
JP2003504343A (ja) * 1999-07-12 2003-02-04 ジェネンテック・インコーポレーテッド 腫瘍壊死因子リガンド／レセプター相同体による血管形成及び心血管形成の促進と抑制
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
AU3075701A (en) * 2000-02-11 2001-08-20 Genentech Inc. Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2168980A1 (de) 2000-06-23 2010-03-31 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US20030059807A1 (en) * 2001-06-07 2003-03-27 Proligo Llc Microcalorimetric detection of analytes and binding events
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ES2200646B1 (es) 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
AU2004249340B2 (en) * 2003-06-25 2011-04-21 Ottawa Hospital Research Institute Use of cardiotrophin to modulate stem cell proliferation
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
JP2010538655A (ja) * 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JP2013507124A (ja) * 2009-10-09 2013-03-04 アナフォア インコーポレイテッド Ｉｌ−２３ｒを結合するポリペプチド
CA2826114A1 (en) * 2011-02-01 2012-08-09 Fate Therapeutics, Inc. Cardiotrophin related molecules for enhanced therapeutics

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552071A (en) * 1978-06-21 1980-01-09 Kuzumaki Ringiyou Kk Turnery working method and its device
JPS5520721A (en) * 1978-07-31 1980-02-14 Nippi:Kk Separation of biologically active material from hematopiesis tissue of domestic animal
US4339441A (en) * 1981-10-30 1982-07-13 Sumner M. Kalman Cardioactive factor
US5017375A (en) * 1982-11-24 1991-05-21 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4900811A (en) * 1983-07-21 1990-02-13 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0233838A3 (de) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neuriten stimulierender Faktor und Prozess für seine Herstellung
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
WO1990009399A1 (fr) * 1989-02-15 1990-08-23 Ono Pharmaceutical Co., Ltd. Nouveau facteur neurotrophique
US5215969A (en) * 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
JP2829755B2 (ja) * 1989-12-27 1998-12-02 株式会社第一ラジオアイソトープ研究所 抗ヒト心筋ｃプロテインモノクローナル抗体及び該抗体を産生するハイブリドーマ
US5214031A (en) * 1990-05-09 1993-05-25 Yoko Uchida Growth-inhibitory factor obtained from human brain
JP2904935B2 (ja) * 1990-10-19 1999-06-14 武田薬品工業株式会社 神経栄養活性抑制物質
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
US5284932A (en) * 1990-09-07 1994-02-08 The Cleveland Clinic Foundation Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth
JPH04124198A (ja) * 1990-09-12 1992-04-24 Sumitomo Pharmaceut Co Ltd 神経栄養ペプチド誘導体
WO1992011026A1 (en) * 1990-12-21 1992-07-09 Case Western Reserve University Neuronal cholinergic differentiation factor
DE69233492D1 (de) * 1991-04-22 2005-04-28 Nasa Aktivitätsabhängiger neurotropher faktor
AU2010592A (en) * 1991-05-20 1992-12-30 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
NZ243084A (en) * 1991-06-12 1995-08-28 Regeneron Pharma Production and recovery of recombinant neurotrophins, genes for a modified lamb signal sequence, fusion genes and plasmids
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
WO1994005788A1 (en) * 1991-09-12 1994-03-17 Sumitomo Pharmaceuticals Company, Limited Neurotrophic peptide
DE69233407T2 (de) * 1991-09-20 2005-09-08 Amgen Inc., Thousand Oaks Glial neurotrophe faktor
EP0607247A1 (de) * 1991-10-01 1994-07-27 Genentech, Inc. Herstellung des gpa neurotrophen faktors
WO1993018065A1 (en) * 1992-03-10 1993-09-16 Mochida Pharmaceutical Co., Ltd. Physiologically active proteinaceous substance
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
DE69333229T2 (de) * 1992-06-04 2004-08-12 University Of Southern California, Los Angeles Verfahren zur reinigung eines neurotrophen faktors aus pigmentiertem retinalen epithelgewebe
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor

Also Published As

Publication number Publication date
CA2188017A1 (en) 1995-11-02
US5624806A (en) 1997-04-29
ES2276393T3 (es) 2007-06-16
MX9604985A (es) 1998-05-31
DK0755446T3 (da) 2007-01-29
WO1995029237A1 (en) 1995-11-02
US5723585A (en) 1998-03-03
ATE339503T1 (de) 2006-10-15
US5571675A (en) 1996-11-05
DE69535221T2 (de) 2007-09-13
EP0755446B1 (de) 2006-09-13
AU697165B2 (en) 1998-10-01
US5627073A (en) 1997-05-06
JP3906314B2 (ja) 2007-04-18
JPH09512427A (ja) 1997-12-16
EP0755446A1 (de) 1997-01-29
AU2635395A (en) 1995-11-16
CA2188017C (en) 2010-09-28
US5679545A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
ATE339503T1 (de) Cardiotrophin und verwendung davon
DE69827126D1 (de) Verwendung von hypothalamus-hemmfaktor zur behandlung von ischämischen herzstörungen
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE188969T1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
EP0653940A4 (de) Glialmitogene faktoren, ihre herstellung und verwendung.
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE302272T1 (de) Neutrokin alpha
ATE113295T1 (de) Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
MY128370A (en) Pyrrolotriazane inhibitors of kinases
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
SE9102079D0 (sv) Purified ciliary neurotrophic factor
DE3686622D1 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
DE3674246D1 (de) Behandlung von sauerem kohlenwasserstoffdestillat.
BG96513A (bg) Заместени 4-фенил-4-пиперидинкарбоксамиди с локален обезболяващ и болкоуспокояващ ефект и метод за тяхното получаване
DE3752062D1 (de) Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
ATE155485T1 (de) Bpc-peptide, ihre herstellung und verwendung
WO1997030146A3 (en) Cardiotrophin and uses therefor
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
DE69022776D1 (de) Verwendung von keramischen Materialen als Ersatzmaterialien für lebendes Gewebe.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition